Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 7, 2013, Pages 668-671

  Clini, Enrico M ^a,b   Beghé, Bianca ^a,c   Fabbri, Leonardo M ^a,c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Villa Pineta Hospital   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

AGING; ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DIET; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; EDITORIAL; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LONG TERM CARE; LUNG FUNCTION; MORTALITY; OBESITY; OSTEOPOROSIS; OXYGEN THERAPY; POLLUTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; SMOKING; SURVIVAL RATE; SYMPTOM;

CACHEXIA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MENTAL DISORDERS; METABOLIC DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84875855314     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201302-0230ED     Document Type: Editorial

References (33)

1. Salive ME. Multimorbidity in older adults. Epidemiol Rev (In press)
2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
3. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, Meinow B, Fratiglioni L. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10:430-439.
4. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706-711.
5. Sin DD, Macnee W. Chronic obstructive pulmonary disease and cardiovascular diseases: a "vulnerable" relationship. Am J Respir Crit Care Med 2013;187:2-4.
6. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev RespirMed 2011;5:647-662.
7. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
8. Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VPM, Bruijnzeel PLB, Rutten EPA, Op't Roodt J, Wouters EFM, Franssen FME. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
9. Ekström MP, Bornefalk Hermansson A, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: a time-dependent analysis. Am J Respir Crit Care Med 2013;187:715-720.
10. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013;187:347-365.
11. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
12. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e637S-e668S.
13. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity society and the American Society of Hypertension. J Clin Hypertens (Greenwich) 2013;15:14-33.
14. Luppi F, Franco F, Beghè B, Fabbri LM. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:848-856.
15. Fabbri LM, Boyd C, Boschetto P, Rabe KF, Buist AS, Yawn B, Leff B, Kent DM, Schünemann HJ; ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. How to integrate multiple comorbidities in guideline development: article 10 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 2012;9:274-281.
16. Ekström MP, Jogréus C, Ström KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE 2012;7:e35806.
17. Ringbaek TJ, Viskum K, Lange P. BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy. Chron Respir Dis 2004;1:71-78.
18. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNeeW. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769-774.
19. Fimognari FL, Scarlata S, Antonelli-Incalzi R. Why are people with "poor lung function" at increased atherothrombotic risk? A critical review with potential therapeutic indications. Curr Vasc Pharmacol 2010;8:573-586.
20. Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, Gajic O. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:376-380.
21. Lahousse L, van den Bouwhuijsen QJA, Loth DW, Joos GF, Hofman A, Witteman JCM, van der Lugt A, Brusselle GG, Stricker BH. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam study. Am J Respir Crit CareMed 2013;187:58-64.
22. Eikelboom JW, Hirsh J, Spencer FA. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e89S-e119S.
23. Ponicke K, Sternitzky R, Mest HJ. Stimulation of aggregation and thromboxane A2 formation of human platelets by hypoxia. Prostaglandins Leukot Med 1987;29:49-59.
24. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-2618.
25. Cohen AT, Spiro ET, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, et al.; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368:513-523.
26. Jindal SK, Agarwal R. Long-term oxygen therapy. Expert Rev Respir Med 2012;6:639-649.
27. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
28. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 2012;186:11-16.
29. Cazzola M, Matera MG. Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am J Respir Crit Care Med 2008;178:661-662.
30. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta agonists. J Am Coll Cardiol 2011;57:2127-2138.
31. Cockcroft JR, Pedersen ME. b-blockade: benefits beyond blood pressure reduction? J Clin Hypertens 2012;14:112-120.
32. Rosenberg SR, Kalhan R. Dying from, and with, chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:960-962.
33. Salisbury C. Multimorbidity: redesigning health care for people who use it. Lancet 2012;380:7-9.